Internal Medicine, Gastroenterology · Katy, TX
NPI
1225142623
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
6
Medicare group memberships
Hospitals
7
Hospital affiliations
1259 Fm 1463 Rd Ste 500
Katy, TX, 77494
Phone (832) 443-3725
Groups this clinician bills Medicare through
Medicare paid, 2024
$344K
5,721 services
Medicare patients, 2024
847
Average age 71
Drug cost, 2024
$871K
5,976 prescriptions
Company payments, 2025
$3,119
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dharmendra Verma was code 88305 (surgical pathology examination), 1,063 times for 233 patients. In total Dharmendra Verma billed 5,721 services in 44 codes, and Medicare paid $344K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 1,063 | 233 | $26.21 | $28K |
| 99214 Office E&M - Established | Office | 950 | 506 | $90.00 | $85K |
| 88313 Surgical Pathology Examination | Office | 388 | 113 | $52.59 | $20K |
| 88312 Surgical Pathology Examination | Office | 364 | 113 | $64.13 | $23K |
| 99213 Office E&M - Established | Office | 304 | 244 | $62.70 | $19K |
| 43239 Upper GI Endoscopy | Facility | 217 | 208 | $76.68 | $17K |
| 45380 Lower GI Endoscopy - Other | Facility | 209 | 206 | $113.04 | $24K |
| 99204 Office E&M - New | Office | 208 | 208 | $113.26 | $24K |
| 99203 Office E&M - New | Office | 135 | 135 | $71.67 | $9,675 |
| 45385 Colonoscopy - Lesion Removal | Facility | 111 | 109 | $195.95 | $22K |
| 46221 Digestive/Gastrointestinal | Office | 102 | 42 | $203.91 | $21K |
| 43249 Upper GI Endoscopy | Facility | 22 | 22 | $100.41 | $2,209 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 16 | 16 | $168.93 | $2,703 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 15 | 15 | $160.33 | $2,405 |
| 91110 Standard X-ray | Office | 12 | 12 | $536.02 | $6,432 |
By year: 2022 $306K for 4,200 services; 2023 $287K for 6,597 services; 2024 $344K for 5,721 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 1,063 | 233 | $26.21 | $28K |
| 88313 Surgical Pathology Examination | 388 | 113 | $52.59 | $20K |
| 88312 Surgical Pathology Examination | 364 | 113 | $64.13 | $23K |
Medicare prescription drug claims, 2024
In 2024, the drug Dharmendra Verma prescribed most often to Medicare patients was Famotidine, with 1,220 prescriptions and refills. In total Dharmendra Verma wrote 5,976 Medicare prescriptions that cost $871K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 1,220 | 2,558 | 421 | $16K |
| Pantoprazole Sodium Generic | 1,185 | 2,447 | 391 | $11K |
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 639 | 639 | 612 | $104K |
| Omeprazole Generic | 444 | 835 | 163 | $5,644 |
| Dicyclomine Hcl Generic | 428 | 507 | 178 | $7,315 |
| Sucralfate Generic | 192 | 234 | 78 | $6,923 |
| Linzess Linaclotide | 141 | 183 | 48 | $98K |
| Metronidazole Generic | 102 | 102 | 95 | $1,046 |
| Ondansetron Odt Ondansetron | 92 | 94 | 51 | $2,687 |
| Ondansetron Hcl Generic | 90 | 94 | 39 | $2,265 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 77 | 77 | 71 | $1,231 |
| Esomeprazole Magnesium Generic | 71 | 87 | 24 | $1,381 |
| Creon Lipase/Protease/Amylase | 71 | 78 | 19 | $131K |
| Budesonide Dr Budesonide | 69 | 100 | 23 | $6,356 |
| Prednisone Generic | 66 | 77 | 16 | $340 |
Brand drugs: - claims; generic drugs: 4,760 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dharmendra Verma $3,119 ($1,305 in general payments such as food, travel and fees and $1,814 for research) from 17 companies. The largest payer was Sanofi US Services Inc. with $1,814.
| Company | Payments | Amount |
|---|---|---|
| Sanofi US Services Inc. SNY | 10 | $1,814 |
| Abbvie Inc. ABBV | 18 | $331 |
| Janssen Biotech, Inc. JNJ | 3 | $186 |
| CONMED Corporation CNMD | 1 | $156 |
| Medtronic, Inc. MDT | 1 | $138 |
| Echosens North America, Inc. | 2 | $104 |
| Janssen Scientific Affairs, LLC JNJ | 1 | $94.88 |
| Madrigal Pharmaceuticals MDGL | 1 | $77.04 |
| Ardelyx, Inc. ARDX | 2 | $52.92 |
| Merit Medical Systems Inc MMSI | 1 | $48.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.